In a few months, you will retire from Harvard University and be free to direct your colossal talents wherever you want. I’m writing with an idea of how you could contribute to the climate change mitigation effort in a way no-one else can, and in the process, reverse what I think may be the only blemish on your otherwise outstanding record: forsaking the divestment movement.
In July, at the U.S. symposium, six Amgen Scholars shared what they love about science. From the power of energy to the magic of molecules, these students share their unique perspectives on what drives their research.
"It was absolutely amazing to be able to speak with experienced researchers at the symposium about the science, and career paths in science. Attending the symposium helped confirmed my decision to pursue a career in academic medicine."
Host University: National Institutes of Health
Home University: Harvard University
Amgen Scholar Year: 2016
Major: Human and Developmental Regenerative Biology
Any Amgen Scholar would be fortunate to land in David Mooney’s cell and tissue engineering lab at Harvard University. In the past year alone, his team of 40 scientists -- 10 of them undergraduates -- has packaged cancer vaccines into new scaffold-like materials. They’ve made elastic gels on which bone stem cells stand a better chance of survival. And they have developed strands of nanomaterials that can deliver drug “refills” to existing drug-eluting implants.
The renewables industry can use lessons learned from serving big business to get universities off old-school fossil fuel energy.
In 2015, corporations bought roughly 3.2 gigawatts (GW) of electricity from utility-scale renewable energy facilities, which generate power from sources like wind and solar and then pump it into the grid to supply energy to utilities and other customers. Indeed, corporations surpassed utilities last year as the majority buyers of wind power. But universities may be the next big customer for utility-scale renewable energy.